Latin American Patients With Diabetes Prefer SGLT2 Inhibitors Latin American Patients With Diabetes Prefer SGLT2 Inhibitors
Findings from a recent study highlight the need for clear discussions between patients and physicians before defining a treatment strategy.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - June 27, 2022 Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news

SGLT2 Inhibitors vs GLP-1 Agonists: Go It Alone or Join Forces? SGLT2 Inhibitors vs GLP-1 Agonists: Go It Alone or Join Forces?
Should SGLT2 Inhibitors and GLP-1 agonists be prescribed singly or jointly? Drs Matthew Budoff and Yehuda Handelsman discuss the options.American College of Cardiology & Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 22, 2022 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

Empagliflozin Eyed for Outpatient Chronic Hyponatremia Empagliflozin Eyed for Outpatient Chronic Hyponatremia
The SGLT2 inhibitor increased sodium and reduced neurocognitive dysfunction in patients with chronic hyponatremia due to the syndrome of inappropriate antidiuresis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 21, 2022 Category: Consumer Health News Tags: Nephrology News Source Type: news

Could a Type 2 Diabetes Drug Tackle Kidney Stones? Could a Type 2 Diabetes Drug Tackle Kidney Stones?
A pooled data analysis of trials of the SGLT2 inhibitor empagliflozin in type 2 diabetes suggests it may lower the risk of kidney stones. However, this is early research.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - June 20, 2022 Category: Primary Care Tags: Nephrology News Source Type: news

SGLT2 Inhibitors Cut AFib Risk in Real-Word Analysis SGLT2 Inhibitors Cut AFib Risk in Real-Word Analysis
Observational data add to a growing link between SGLT2 inhibitor treatment and atrial fibrillation prevention in people with type 2 diabetes.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 14, 2022 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Dapagliflozin Early Benefit Explored in Reduced-EF Heart Failure Dapagliflozin Early Benefit Explored in Reduced-EF Heart Failure
Why have SGLT2-inhibitor clinical benefits in HFrEF trials been evident so soon after the drugs are started? Recent studies shed light on one potential mechanism among what are probably many.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 6, 2022 Category: Consumer Health News Tags: Cardiology News Source Type: news

ADA Prioritizes Heart Failure in Patients With Diabetes ADA Prioritizes Heart Failure in Patients With Diabetes
Patients with diabetes should have annual screening for biomarkers of early-stage heart failure, and treatment should prioritize an SGLT2 inhibitor, said an American Diabetes Association panel.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 2, 2022 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

ADA Updates on Finerenone, SGLT2 Inhibitors, and Race-Based eGFR ADA Updates on Finerenone, SGLT2 Inhibitors, and Race-Based eGFR
ADA has made an interim change to its latest Standards of Medical Care, an update based on trial evidence and consensus about finerenone, SGLT2 inhibitors, and eGFR.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - June 1, 2022 Category: Intensive Care Tags: Diabetes & Endocrinology News Source Type: news

SGLT2 Inhibitor Use Not Tied to Increased Fracture Risk in CKD
WEDNESDAY, June 1, 2022 -- For older adults, initiation of a sodium-glucose cotransporter-2 (SGLT2) inhibitor is not associated with higher fracture risk compared with initiation of a dipeptidyl peptidase-4 (DPP-4) inhibitor, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 1, 2022 Category: Pharmaceuticals Source Type: news

Do SGLT2 Inhibitors Impact Fractures in Diabetic Kidney Disease? Do SGLT2 Inhibitors Impact Fractures in Diabetic Kidney Disease?
Study provides real-world assurance that SGLT2 inhibitors have no added risk of fracture in patients with mainly mild kidney disease after a year of use. But follow-up was short, say experts.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - May 31, 2022 Category: Drugs & Pharmacology Tags: Diabetes & Endocrinology News Source Type: news

SGLT2 Inhibitors a Better First Drug in Type 2 Diabetes Than Metformin?
(MedPage Today) -- Using SGLT2 inhibitors in the first-line treatment of type 2 diabetes lowered some cardiovascular risk, a claims database study showed. The combined 12-month risk for myocardial infarction (MI), stroke, and death was similar... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 23, 2022 Category: Cardiology Source Type: news

May 13 2022 This Week in Cardiology May 13 2022 This Week in Cardiology
Obstructive hypertrophic cardiomyopathy and mavacamten, SGLT2 inhibitors, the triple whammy, espresso, and clinician burnout are the topics John Mandrola, MD, covers in today ’s podcast.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 13, 2022 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

Positive Topline Results for Dapagliflozin in HFpEF: DELIVER Positive Topline Results for Dapagliflozin in HFpEF: DELIVER
AstraZeneca says regulatory submissions will be forthcoming, potentially bringing a second SGLT2 inhibitor in this space, after empagliflozin.News Alerts (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - May 5, 2022 Category: Internal Medicine Tags: Cardiology News Alert Source Type: news

Suggestions for Successful SGLT2i Use in Glomerular Disease Suggestions for Successful SGLT2i Use in Glomerular Disease
Findings from recent trials further support the benefits of SGLT2 inhibitors in the management of glomerular disease. This review provides guidance for successful implementation.Current Opinion in Nephrology and Hypertension (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 5, 2022 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news

SGLT2 Inhibitor Safe for Kidneys in Hospitalized COVID Patients
(MedPage Today) -- Taking sodium-glucose cotransporter-2 (SGLT2) inhibitor dapagliflozin (Farxiga) didn't hinder renal outcomes for patients hospitalized with COVID-19, according to a secondary analysis of the DARE-19 trial. Among patients with... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 29, 2022 Category: Cardiology Source Type: news